<DOC>
	<DOC>NCT02387814</DOC>
	<brief_summary>The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated. This study will last approximately 3 weeks for each participant, including check-in and follow-up.</brief_summary>
	<brief_title>A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Female participants must be of nonchildbearing potential Have a body mass index of 18 to 40 kilograms per square meter (kg/m^2) No history of cardiovascular, renal, respiratory, gastrointestinal, endocrine or hematological disorders Have known allergies to abemaciclib, related compounds, or any components of the formulation No human immunodeficiency virus (HIV) infection or antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>